EVENT ANAB-JEMPERLIDOST-2026
SCORED SET not stated
FLOOR floor_cCR_durability Floor: the AZUR-1 disclosure must establish clinical complete-response durability at 12 months ["In July 2026, GSK announced positive interim results from the trial, which met its primary objective by demonstrating a meaningful and sustained clinical complete response rate for 12 months (cCR12) with no detectable signs of cancer for at least one year"].
BAR bar_rectal_complete_response Bar: the AZUR-1 clinical complete-response rate should be at least as good as the prior dostarlimab rectal complete-response result, 100% ["Recent data published in The New England Journal of Medicine (NEJM) and presented at American Association for Cancer Research (AACR) demonstrated neoadjuvant treatment with dostarlimab resulted in organ preservation in a high proportion of patients (80% of 103 patients), including 100% (rectal; n=49), 100% (bladder; n=6), and 82% (colon; n=22) complete responses in April 2025"].
DIFF diff_organ_preservation Organ preservation should at least match the prior dostarlimab benchmark ["Recent data published in The New England Journal of Medicine (NEJM) and presented at American Association for Cancer Research (AACR) demonstrated neoadjuvant treatment with dostarlimab resulted in organ preservation in a high proportion of patients (80% of 103 patients), including 100% (rectal; n=49), 100% (bladder; n=6), and 82% (colon; n=22) complete responses in April 2025"].